What is the appropriate clindamycin dosage for adults and children, including adjustments for hepatic impairment and recommended treatment duration?

Clindamycin Dosing

For adults with serious infections, use clindamycin 150-300 mg orally every 6 hours or 600-900 mg IV every 8 hours; for more severe infections, increase to 300-450 mg orally every 6 hours or 900 mg IV every 8 hours, with pediatric dosing at 8-20 mg/kg/day divided into 3-4 doses based on severity. 1

Adult Dosing

Oral Administration

• Serious infections: 150-300 mg every 6 hours 1
• More severe infections: 300-450 mg every 6 hours 1
• Must be taken with a full glass of water to avoid esophageal irritation 1
• Absorption is virtually complete (90%) and not affected by food 1

Intravenous Administration

For skin and soft tissue infections:

• Complicated SSTI: 600 mg IV every 6-8 hours 2
• Purulent cellulitis (outpatient): 300-450 mg PO three times daily 2
• Necrotizing infections with Streptococcus: 600-900 mg IV every 8 hours (combined with penicillin) 2
• Clostridial myonecrosis: 600-900 mg IV every 8 hours (combined with penicillin) 2

For bone and joint infections:

• Osteomyelitis/septic arthritis: 600 mg IV/PO three times daily 2

For pneumonia:

• 600 mg IV/PO three times daily 2

Dosing Optimization

• For intraabdominal infections, 900 mg IV every 8 hours achieves significantly higher cure rates (90.5%) compared to 600 mg every 8 hours (75.6%), though success rates are similar 3
• The 900 mg every 8 hours regimen produces significantly higher peak concentrations while maintaining comparable trough levels and AUC to 600 mg every 6 hours 4

Pediatric Dosing (Beyond Neonatal Period)

Oral Administration

• Serious infections: 8-16 mg/kg/day divided into 3-4 equal doses 1
• More severe infections: 16-20 mg/kg/day divided into 3-4 equal doses 1
• Only for children able to swallow capsules whole; use oral solution otherwise 1

Intravenous Administration

• Skin and soft tissue infections: 10-13 mg/kg/dose IV every 6-8 hours, not to exceed 40 mg/kg/day 2
• Bone and joint infections: 10-13 mg/kg/dose IV every 6-8 hours, not to exceed 40 mg/kg/day 2
• Pneumonia: 10-13 mg/kg/dose IV every 6-8 hours, not to exceed 40 mg/kg/day 2

Pediatric Dosing Considerations

• Dose based on total body weight regardless of obesity 1
• For musculoskeletal infections in MRSA-prevalent communities, 30 mg/kg/day orally is effective and shows no difference in readmission rates compared to 40 mg/kg/day, with potentially fewer sequelae 5
• For osteomyelitis, 50 mg/kg/day IV for approximately 3 weeks followed by 30 mg/kg/day orally for 6 additional weeks has shown excellent outcomes 6
• Tetracyclines should not be used in children <8 years of age 2

Hepatic Impairment

No dose adjustment is required for hepatic impairment, but use with caution and monitor closely. 1

• The elimination half-life increases slightly in patients with markedly reduced hepatic function 1
• In a study of patients with acute hepatitis, chronic hepatitis, and cirrhosis, there was only a small but significant delay in drug elimination in cirrhotics compared to controls, with half-lives remaining in the normal range 7
• Clindamycin did not exacerbate preexisting hepatic dysfunction in these patients 7
• Dosage schedules do not need modification in hepatic disease, but proper precautions should be exercised 1, 7

Renal Impairment

No dose adjustment is required for renal impairment. 1

• Dosage schedules do not need modification in patients with renal disease 1
• Hemodialysis and peritoneal dialysis are not effective in removing clindamycin 1

Geriatric Considerations

No dose adjustment is necessary for elderly patients with normal hepatic function and age-adjusted renal function. 1

• The average elimination half-life increases to approximately 4 hours in elderly patients (61-79 years) compared to 3.2 hours in younger adults 1
• The extent of absorption is not different between age groups 1

Treatment Duration

General Infections

• Skin and soft tissue infections: 5-10 days, individualized based on clinical response 2
• β-hemolytic streptococcal infections: At least 10 days 1
• Animal/human bites: Duration not specified but typically 5-7 days 2

Specific Infections

• Osteomyelitis (pediatric): Approximately 3 weeks IV followed by 6 weeks oral 6
• Musculoskeletal infections (pediatric): Average 32.8 days outpatient treatment 5

Critical Drug Interactions

When clindamycin is combined with rifampicin, oral administration is contraindicated and IV doses must be substantially increased. 8

• Rifampicin increases clindamycin clearance by a factor of 3 8
• Rifampicin dramatically reduces clindamycin bioavailability in a dose-dependent manner (from 56% to 11% with rifampicin 600 mg, and to 4% with rifampicin 900 mg every 12 hours) 8
• When combined with rifampicin, use at least 3600-4800 mg/day IV by intermittent infusion or preferably continuous infusion 8
• Clindamycin is predominantly metabolized by CYP3A4, with minor contribution from CYP3A5 1, 9

Important Safety Considerations

• Discontinue immediately if significant diarrhea occurs due to risk of Clostridioides difficile-associated disease 1
• C. difficile-associated disease may occur more frequently with clindamycin compared to other oral agents 2
• Clindamycin is pregnancy category B 2
• Take capsules with a full glass of water to avoid esophageal irritation 1